Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Authors

• William Kelly

Publication/Presentation Date

2-2019

Volume

37

Issue

7

Published In/Presented At

DOI: 10.1200/JCO.2019.37.7_suppl.202

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article